Barrington, Ill. - The National Rosacea Society (NRS) has awarded funding to four new studies aimed at learning more about the causes and management of rosacea.
An NRS press statement announced funding for the following studies:
- $25,000 to Richard Gallo, M.D., chief of the division of dermatology, University of California San Diego, and Kenshi Yamasaki, M.D., of the Veterans Medical Research Foundation, to continue their ongoing research into the role cathelicidins may play in the development of subtype 2 (papulopustular) rosacea.
- $25,000 to Yolanda Helfrich, M.D., assistant professor of dermatology, University of Michigan, for a study comparing subtype 1 (erythematotelangiectatic) rosacea and photoaging, both of which may include the development of telangiectasia and erythema.
- $25,000 to Richard Granstein, M.D., chairman of dermatology, Cornell University, and colleagues to continue their research on the role of adenosine triphosphate (ATP) in recruiting inflammatory cells in subtype 2 rosacea.
- $25,000 to Martin Steinhoff, M.D., of the department of dermatology, University of Muenster, Germany. Dr. Steinhoff will study the role of neuroimmune interactions in the pathophysiology of rosacea.